Privium Fund Management B.V. Buys 236,279 Shares of ProQR Therapeutics (NASDAQ:PRQR)

Privium Fund Management B.V. boosted its stake in ProQR Therapeutics (NASDAQ:PRQR) by 4.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,580,725 shares of the biopharmaceutical company’s stock after acquiring an additional 236,279 shares during the period. ProQR Therapeutics accounts for about 2.4% of Privium Fund Management B.V.’s holdings, making the stock its 11th biggest position. Privium Fund Management B.V. owned about 6.86% of ProQR Therapeutics worth $9,208,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. EP Wealth Advisors LLC bought a new stake in shares of ProQR Therapeutics in the first quarter valued at approximately $26,000. Acadian Asset Management LLC bought a new stake in shares of ProQR Therapeutics in the first quarter valued at approximately $56,000. RFG Advisory LLC bought a new stake in shares of ProQR Therapeutics in the first quarter valued at approximately $73,000. BNP Paribas Financial Markets raised its position in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 19,100 shares during the period. Finally, Ikarian Capital LLC raised its position in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 10,958 shares during the period. Institutional investors own 32.65% of the company’s stock.

Analyst Ratings Changes

PRQR has been the topic of a number of analyst reports. StockNews.com raised shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 29th. Chardan Capital reaffirmed a “buy” rating and set a $2.50 target price on shares of ProQR Therapeutics in a report on Friday, May 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of ProQR Therapeutics in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $3.38.

ProQR Therapeutics Price Performance

PRQR stock traded up $0.03 during midday trading on Friday, reaching $2.02. The company had a trading volume of 163,816 shares, compared to its average volume of 156,534. ProQR Therapeutics has a 1 year low of $1.11 and a 1 year high of $3.29. The company has a market capitalization of $164.35 million, a P/E ratio of -5.46 and a beta of 0.42. The firm has a 50-day moving average price of $1.87 and a 200-day moving average price of $1.97.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.09. ProQR Therapeutics had a negative net margin of 140.17% and a negative return on equity of 55.42%. The company had revenue of $6.79 million during the quarter, compared to analysts’ expectations of $3.32 million. On average, equities analysts predict that ProQR Therapeutics will post -0.31 EPS for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).